ARTICLE | Company News
Debiopharm acquires Affinium's antibiotic assets
February 12, 2014 1:58 AM UTC
Debiopharm Group (Lausanne, Switzerland) acquired all of the assets of antibiotics company Affinium Pharmaceuticals Ltd. (Austin, Texas), which will now wind down operations. Financial terms of the deal were not disclosed. The assets include Affinium's AFN-1252, a small molecule inhibitor of the bacterial fabI enoyl-(acyl carrier protein) reductase that has completed a Phase IIa trial to treat acute bacterial skin and skin structure infections (ABSSSI), for which the compound has Qualified Infectious Disease Product (QIDP) designation; and AFN-1720, a prodrug of AFN-1252 that is in Phase I testing (see BioCentury, March 17, 2008). ...